Compare BXSL & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BXSL | INDV |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.4B |
| IPO Year | 2018 | 2014 |
| Metric | BXSL | INDV |
|---|---|---|
| Price | $23.63 | $37.01 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $27.18 | N/A |
| AVG Volume (30 Days) | ★ 2.3M | 2.0M |
| Earning Date | 05-07-2026 | 06-08-2026 |
| Dividend Yield | ★ 12.87% | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | 0.11 | ★ 0.69 |
| Revenue | N/A | ★ $1,239,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $215.00 | ★ $55.00 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $22.47 | $12.04 |
| 52 Week High | $32.81 | $41.00 |
| Indicator | BXSL | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 45.18 | 53.36 |
| Support Level | $23.32 | $35.36 |
| Resistance Level | $24.99 | $37.83 |
| Average True Range (ATR) | 0.47 | 1.11 |
| MACD | -0.06 | -0.32 |
| Stochastic Oscillator | 25.30 | 23.56 |
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).